233 related articles for article (PubMed ID: 37524642)
1. Immune vulnerabilities of mutant KRAS in pancreatic cancer.
Cheng NC; Vonderheide RH
Trends Cancer; 2023 Nov; 9(11):928-936. PubMed ID: 37524642
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation in pancreatic cancer.
Luo J
Semin Oncol; 2021 Feb; 48(1):10-18. PubMed ID: 33676749
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.
Bear AS; Blanchard T; Cesare J; Ford MJ; Richman LP; Xu C; Baroja ML; McCuaig S; Costeas C; Gabunia K; Scholler J; Posey AD; O'Hara MH; Smole A; Powell DJ; Garcia BA; Vonderheide RH; Linette GP; Carreno BM
Nat Commun; 2021 Jul; 12(1):4365. PubMed ID: 34272369
[TBL] [Abstract][Full Text] [Related]
4. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
5. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
6. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette GP; Bear AS; Carreno BM
Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
[TBL] [Abstract][Full Text] [Related]
7. Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming.
Velez-Delgado A; Donahue KL; Brown KL; Du W; Irizarry-Negron V; Menjivar RE; Lasse Opsahl EL; Steele NG; The S; Lazarus J; Sirihorachai VR; Yan W; Kemp SB; Kerk SA; Bollampally M; Yang S; Scales MK; Avritt FR; Lima F; Lyssiotis CA; Rao A; Crawford HC; Bednar F; Frankel TL; Allen BL; Zhang Y; Pasca di Magliano M
Cell Mol Gastroenterol Hepatol; 2022; 13(6):1673-1699. PubMed ID: 35245687
[TBL] [Abstract][Full Text] [Related]
8. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
Wang K; Baldwin GS; Nikfarjam M; He H
World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer.
Nauheim D; Moskal D; Renslo B; Chadwick M; Jiang W; Yeo CJ; Nevler A; Bowne W; Lavu H
J Surg Oncol; 2022 Aug; 126(2):314-321. PubMed ID: 35333412
[TBL] [Abstract][Full Text] [Related]
10. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
11. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
13. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
Moss DY; McCann C; Kerr EM
Sci Signal; 2022 Oct; 15(756):eabj3490. PubMed ID: 36256706
[TBL] [Abstract][Full Text] [Related]
14. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
17. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
[TBL] [Abstract][Full Text] [Related]
18. Eicosapentaenoic Acid Inhibits
Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
[TBL] [Abstract][Full Text] [Related]
19. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
20. Kras
Cheng H; Fan K; Luo G; Fan Z; Yang C; Huang Q; Jin K; Xu J; Yu X; Liu C
Cancer Lett; 2019 Apr; 446():103-111. PubMed ID: 30664964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
